PNEUMOCOCCAL VACCINES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)
Segmentation
By Vaccine TypePneumococcal Conjugate Vaccines (PCVs) (PCV13 (Prevnar 13/Prevenar 13), PCV10 (Synflorix), PCV7 (Prevnar/Prevenar)) and Pneumococcal Polysaccharide Vaccines (PPVs) (PPSV23 (Pneumovax 23), PPSV14 (Pneumo 14)) · By Target Population (Adults (≥ 65 years), Children (< 5 years), High-Risk Adults (18-64 years)) · By Route of Administration (Intramuscular, Subcutaneous) · By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) · By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa
Published In01 Apr 2026
Report CodeCMI2295
Pages250+
FormatsExcel and PDF
Base Year2025
Estimated Year2026
Historical Range2020 - 2024
Forecast Period2026-2033
Market Segmentation
By Vaccine Type (Revenue, USD Bn, 2021 - 2033)
Pneumococcal Conjugate Vaccines (PCVs)
PCV13 (Prevnar 13/Prevenar 13)
PCV10 (Synflorix)
PCV7 (Prevnar/Prevenar)
Pneumococcal Polysaccharide Vaccines (PPVs)
PPSV23 (Pneumovax 23)
PPSV14 (Pneumo 14)
By (Revenue, USD Bn, 2021 - 2033)
Target Population
Adults (≥ 65 years)
Children (< 5 years)
High-Risk Adults (18-64 years)
By Route of Administration (Revenue, USD Bn, 2021 - 2033)
